Search
AbbVie Acquires Gilgamesh's Promising MDD Drug Candidate, Bretisilocin
2025-08-26 /
Read about 0 minute
Author：小编
AbbVie has announced an agreement with Gilgamesh Pharmaceuticals to acquire bretisilocin, a groundbreaking investigational drug for the treatment of major depressive disorder (MDD). Currently in Phase II clinical development, bretisilocin functions as both a 5-HT2A receptor agonist and a 5-HT releaser. This innovative drug aims to overcome developmental challenges by utilizing novel psychedelic compounds, which have shown the potential to reduce the duration of psychoactive effects while maintaining long-lasting therapeutic benefits.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
